Dequalinium acetate
| Code | Size | Price |
|---|
| TAR-T0979L-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Dequalinium is a quaternary ammonium cation and bolaamphiphile commonly available as the dichloride salt. The bromide, iodide, acetate, and undecenoate salts are known as well.
CAS:
4028-98-2
Formula:
C34H46N4O4
Molecular Weight:
574.766
Purity:
0.98
SMILES:
CC([O-])=O.CC([O-])=O.Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12
References
1. Yamasaki S, Nakashima R, Sakurai K, Baucheron S, Giraud E, Doublet B, Cloeckaert A, Nishino K. Crystal structure of the multidrug resistance regulator RamR complexed with bile acids. Sci Rep. 2019 Jan 17;9(1):177. doi: 10.1038/s41598-018-36025-8. PubMed PMID: 30655545; PubMed Central PMCID: PMC6336783.
2. Battogtokh G, Choi YS, Kang DS, Park SJ, Shim MS, Huh KM, Cho YY, Lee JY, Lee HS, Kang HC. Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives. Acta Pharm Sin B. 2018 Oct;8(6):862-880. doi: 10.1016/j.apsb.2018.05.006. Epub 2018 May 18. Review. PubMed PMID: 30505656; PubMed Central PMCID: PMC6251809.
3. Sauvage F, Legrand FX, Roux M, Rajkovic I, Weiss TM, Varga Z, Augis L, Nugue G, Debouzy JC, Vergnaud-Gauduchon J, Barratt G. Interaction of dequalinium chloride with phosphatidylcholine bilayers: A biophysical study with consequences on the development of lipid-based mitochondrial nanomedicines. J Colloid Interface Sci. 2019 Mar 1;537:704-715. doi: 10.1016/j.jcis.2018.11.059. Epub 2018 Nov 15. PubMed PMID: 30497059.
4. Cheng AN, Lo YK, Lin YS, Tang TK, Hsu CH, Hsu JT, Lee AY. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach. EBioMedicine. 2018 Oct;36:241-251. doi: 10.1016/j.ebiom.2018.09.030. Epub 2018 Oct 5. PubMed PMID: 30293817; PubMed Central PMCID: PMC6197782.